NEW HAVEN, Conn., Feb. 8, 2010 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of treatments for the most challenging infectious diseases, today announced that Michael D. Kishbauch, President and Chief Executive Officer, will present a corporate and clinical update at the 12th Annual BIO CEO and Investor Conference at The Waldorf Astoria hotel in New York City on Tuesday, February 9, 2010 at 3:30 p.m. Eastern Standard Time.

Mr. Kishbauch's presentation will be webcast and accessible from the News Center section of Achillion's website, www.achillion.com. To ensure a timely connection to the webcast, it is recommended that users register several minutes prior to the scheduled start time. An audio archived version of the webcast will also be available for replay for thirty days following the presentation date.

About Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. Achillion's proven discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease –hepatitis C, resistant bacterial infections and HIV. For more information on Achillion Pharmaceuticals, please visit www.achillion.com or call 1-203-624-7000. 

ACHN-G

CONTACT:  Achillion Pharmaceuticals, Inc.
          Mary Kay Fenton
          (203) 624-7000
          mfenton@achillion.com

          Lippert/Heilshorn & Associates, Inc.
          Investors:
          Anne Marie Fields
            (212) 838-3777
            afields@lhai.com
          Bruce Voss
            (310) 691-7100
            bvoss@lhai.com